The new domestic hypoglycemic medicine is hot! Over 50 Class 1 new drugs hit Hengrui and other 3 major tracks

Since the beginning of this year, domestically produced Class 1 new hypoglycemic drugs have ushered in many new developments.

DPP-4, GLP-1, and SGLT-2 have their own characteristics and advantages.

DPP-4 inhibitors: nearly 4 billion market competition is fierce, and the first domestically produced Class 1 new drug will be born

Dipeptidyl peptidase (DPP-4) inhibitors selectively inhibit DPP-4 activity, increase endogenous GLP-1 and GIP levels, promote insulin release from pancreatic β cells, and inhibit the secretion of glucagon from pancreatic α cells.

Including compound preparations, 10 DPP-4 inhibitors have been approved for marketing in China.

DPP-4 inhibitors listed in China

Note: If less than 50 million yuan is represented by *, the same below

Source: Mi Nei Net Database

The competition for DPP-4 inhibitors is fierce.

Currently, no domestically produced DPP-4 inhibitor Class 1 new drug has been approved, but there are already a number of companies deployed

Some domestic DPP-4 inhibitors under research in China

Note: Only statistics of domestically produced Class 1 new drugs, the same below

Source: China Drug Clinical Trial Publicity Library of Meinenet

Five domestically-made DPP-4 inhibitor Class 1 new drugs have entered Phase III clinical and above stages

GLP-1 receptor agonists: 2 domestically produced Class 1 new drugs have been approved, and these 5 drugs are expected to be on the market

Glucagon-like peptide-1 (GLP-1) receptor agonists belong to the class of secretin drugs.

Including compound preparations, there are currently 9 domestic GLP-1 receptor agonists approved for marketing (2 are domestically produced Class 1 new drugs).

Domestically marketed GLP-1 receptor agonist

Source: Mi Nei Net Database

Among the short-acting GLP-1 receptor agonists, Novo Nordisk's liraglutide was rapidly increased after being negotiated into medical insurance in 2017.

Among the long-acting GLP-1 receptor agonists, Hausen’s polyethylene glycol loxenatide and Eli Lilly’s dulaglutide will be included in the national medical insurance category B list through negotiations in 2020, and H1 will be listed in Chinese public medical care in 2021.

In addition to the two domestically-made GLP-1 receptor agonists that have been approved for marketing, according to incomplete statistics, there are currently 17 domestically-made Class 1 new drugs in phase I and above

Some domestically-developed GLP-1 receptor agonists in China

Source: China Drug Clinical Trial Publicity Library of Meinenet

Five domestically-made GLP-1 receptor agonists have entered a key phase III clinical trial and are expected to be reported for production one after another.

Among other new drugs under development, the TTP273 tablet of East China is the first small molecule non-peptide oral dosage form, which has a differentiated advantage in dosage form from other products under development; 2 are dual receptor agonists, each from Cinda IBI362 injection (GLP-1/GCGR), Dongyang Pharmaceutical's HEC88473 injection (GLP-1/FGF21)

SGLT-2 inhibitors: the market has expanded significantly, Hengrui and Dongyang Sunshine Pharmaceuticals are making great efforts

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors reduce the reabsorption of filtered glucose by the kidneys by inhibiting SGLT-2, lower the renal threshold of glucose, thereby increasing urinary glucose excretion, and are effective for all stages of type 2 diabetes.

Including compound preparations, currently 5 SGLT-2 inhibitors have been approved for marketing in China.

Domestic marketed SGLT-2 inhibitor

Source: Mi Nei Net Database

Except for Egliflozin tablets, the other 4 SGLT-2 inhibitors have been approved for the listing of generic drugs and deemed to have been reviewed.
Among them, canagliflozin and empagliflozin have been included in the fourth batch of centralized procurement, due to the late listing , The impact of superimposed centralized procurement has not fully appeared.
The two products will still have a sales growth rate of more than 500% and 200% in the H1 Chinese public medical institution terminal in 2021
.

Currently, no domestically produced SGLT-2 inhibitor Class 1 new drug has been approved, but there are already many companies deployed
.
According to incomplete statistics, there are currently 8 domestically-made Class 1 new drugs at the stage of clinical approval and above, and the research and development progress of Hengrui, Dongyangyang Pharmaceutical and Xuanzhu Pharmaceutical is ahead
.

Some domestic SGLT-2 inhibitors under development in China

Source: China Drug Clinical Trial Publicity Library of Meinenet

Hengligliflozin of Hengrui Medicine has submitted an NDA and is expected to win the first domestically produced SGLT-2 inhibitor Class 1 new drug; Dongyang Pharmaceutical’s Rongligliflozin is undergoing phase III clinical trials and is expected to complete phase III clinical trials in 2022.
Submit a listing application
.

Source: Mi Nei Net Database

Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of November 11, if there are any omissions, please correct me!